Abstract.-Repeated administration of potent mouse interferon preparations increased the survival of Balb/c and C 57/B16 mice inoculated with 2,000-3,000 RC19 and EL4 tumor cells. Only 7/188 (3.7%') untreated mice (or mice treated with control preparations) survived more than 22 days after intraperitoneal inoculation of RC19 tumor cells. None survived more than 60 days. In contrast, 101/103 (981%) interferon-treated mice survived beyond 22 days, and sixteen (15%O) survived more than 60 days. None of these 16 surviving mice show any sign of tumor at present. Three mice (of the 16) from an early experiment are alive ten months after inoculation of RC19 tumor cells.
preparation of mouse brain interferon was as effective as crude brain interferon. Human amniotic membrane interferon and control tissue preparations were without effect. These findings suggest that interferon itself (or a factor closely associated with interferon) is the active moiety in these preparations.
Introduction.-We have previously reported that the repeated administration of interferon preparations delayed the evolution of Friend and Rauscher leukemias in mice.l 2 Although it seemed likely that interferon acted by repressing viral multiplication, it was emphasized that a direct action of interferon on the proliferation of viral-infected transformed cells had not been excluded. 3' 4 To explore this possibility, Balb/c or C 57/B16 mice were inoculated with RC19 or EL4 tumor cells and treated daily with interferon preparations. We report here that this treatment resulted in a marked increase in the survival of tumor-inoculated mice.* Materials and Methods.-Mice: One-month-old male and female Balb/c and Cr7/Bl6 mice were obtained from the breeding colony of the Institut de Recherches sur le Cancer. There was no statistically significant difference between male and female mice in their response to inoculation of tumor cells or to interferon treatment. Accordingly, in all experiments, equal numbers of male and female Balb/c and C 57/B16 mice were grouped for statistical analysis.
Tumor cells: (1) The RC19 ascitic cell line originated from Balb/c mice inoculated with Rauscher virus (laboratory of Dr. J. P. Levy) . Electron microscopic examination of the cells reveals the presence of occasional type C virions.
(2) The EL4 ascitic cell line was derived in 1945 from C 57/B1 mice inoculated with 9:10 dimethyl-1:2 benzanthracene. A significant increase in mouse survival was observed (as determined both by the number of mice surviving more than 22 days and the mean survival in days) when interferon preparations were injected i.p. (0.25 ml) 24 hours after inoculation of tumor cells and daily thereafter for 2 months (Table 1 ). This increased survival was noted after treatment of mice with mouse brain interferon (expts. 1-4, 6), serum interferon (expt. 1), or cell culture interferon (expt. 5).
A purified preparation of mouse brain interferon proved as effective as a crude interferon preparation (expt. 4). Administration of human interferon (expt. 6) or control preparations did not increase the survival of tumor-bearing mice, and in two experiments (expts. 1 and 3) inoculation of a normal brain or serum preparation shortened the survival time.
As can be seen from experiment 1 (Table 1) subcutaneous inoculation of mouse brain interferon also increased survival (mean survival, 23 days, control (Table 1) interferon treatment was initiated 24 hours after inoculation of tumor cells and daily for the ensuing six days. These mice were subsequently maintained without treatment for the remainder of the experiment. In a second group, interferon treatment was initiated one week after inoculation of tumor cells.
There was no significant difference in survival between these two groups of mice. Both groups survived longer (mean 27 and 26 days) than the control groups of mice (mean 18-19 days), but neither treatment schedule was as effective as an interferon treatment initiated 24 hours after inoculation of tumor cells and continued daily throughout the experiment (mean 42 days).
(c) Effect of intraperitoneal interferon administration on the survival of Balb/c mice inoculated subcutaneously with RC19 cells: In two experiments, one-monthold male and female Balb/c mice were inoculated subcutaneously in the interscapsular region with approximately 100 RC19 cells. In one of these experiments, daily i.p. inoculation of 20,000 units of mouse brain interferon delayed the appearance and growth of subcutaneous tumor nodules and increased survival (mean survival for control mice, 26 days; for interferon-treated mice, 36 days). In a second experiment, however, no difference could be demonstrated between untreated and interferon-treated mice.
(2) Effect of mouse brain interferon preparations on the survival of C 57/BL6 mice inoculated intraperitoneally with EL4 cells: One-month-old male and female C 57/B16 mice were inoculated i.p. with 2,000-3,000 EL4 tumor cells (equivalent of 400-600 LDso). Untreated mice or mice treated with control preparations died 15-26 days (mean 19 days) after tumQr cell inoculation.
PV.31 9 Y OOGY: GRESaSER ET AL. Mouse brain interferon treatment (i.p.) initiated 24 hours after the inoculation of 2,000-3,000 EL4 tumor cells and continued daily thereafter significantly increased the survival of C 57/Bl6 mice (Table 3 ) (mean survival for control mice, 19-20 days; for interferon-treated mice, 25 or 27 days). At autopsy, EL4 tumors appeared more solid and invasive than RC,9 tumors in Balb/c mice and only minimal ascites was present. No significant difference was observed between control and interferon-treated mice.
Discussion.-The repeated administration of potent mouse interferon preparations increased the survival of Balb/c and C 57/B16 mice inoculated intraperitoneally with 2,000-3,000 RC19 and EL4 tumor cells. Several findings suggest that interferon itself (or a factor intimately associated with interferon) was responsible for the effects observed: (1) suggested, however, that the antitumor effects of the synthetic polynucleotides may not have been related to the induction of interferon.
The explanation for the increased survival of interferon-treated mice inoculated with tumor cells is not apparent. Interferon preparations (or a hypothetical associated factor) may have acted on the mouse, enhancing mechanisms of tumor cell rejection, or directly on the tumor cells themselves. Several experimental observations support this latter hypothesis. Interferon treatment appeared most effective when intimate contact between cell suspensions (ascites) and interferon was maximal (i.e., RC,9 cells and interferon both inoculated intraperitoneally). The finding that solid tumor masses developed intra-and extraperitoneally in spite of interferon treatment (ascites was rarely observed in these mice) may have reflected the relatively diminished contact between individual cells and the interferon preparations.
As regards the possible direct effect of interferon preparations on cellular growth, Paucker, Cantell, and Henle'4 reported that exposure of L-cells to interferon resulted in a depression of cellular replication depending on the antiviral potency of the interferon preparations utilized and the duration of the incubation period. Paucker and Golgher recently observed similar effects with purified preparations of mouse interferon.' Dubbs and Scherer suggested that interferon might have been responsible for the inhibition of the growth of L-cells in cultures inoculated with Japanese encephalitis virus.'6 Baron and his co-workers could not consistently confirm these findings and attributed the occasional inhibition of L-cell growth to "noninterferon contaminants."17 Furthermore, they found that purified chicken interferon did not inhibit the growth of chick embryo cells.'7 (An important difference may exist, however, between the response of primary and secondary cultures of "normal" chick fibroblasts to interferon preparations and that of a cell line, L-cells.)
The RC,9 cell line was derived initially from the spleen of a mouse inoculated with Rauscher virus. Type C virions are observed on electron microscopic examination, and infectious virus can be recovered from these cells. The EL4 cell line was derived from a mouse exposed to a chemical carcinogen. Biologically active virus has not been recovered from EL4 cells, and no known specific viral antigen has been detected.'8 Nevertheless, these cells contain numerous type A intracellular "viral particles," similar to those frequently associated with murine tumors."9 It seems possible, therefore, that the antitumor effect of interferon in our experiments was mediated by its antiviral property, although it is difficult at present to explain the mechanism of action.
